Contributions
Abstract: P576
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Neuropsychology
Background: Fampridine is an oral treatment that has been shown to promote the conduction in demyelinated axons in Multiple Sclerosis (MS). It acts blocking the potassium channels, improving the gait. Some central nervous system secondary effects may appear, but it does not seem to affect cognitive functions. Several factors (lesion mechanism, conduction impairment, etc.) have been associated to cognitive impairment in MS, although the pathogenesis of deficits in specific functions is under discussion. The aim of this study was to compare the cognitive performance between responders and non-responders to this treatment.
Methods: Retrospective study of a cohort of patients treated with fampridine. Walking speed was evaluated at baseline and 1 month after the onset of treatment. Exhaustive cognitive assessment was performed, using several tests of attention and executive function, processing speed, verbal and visual memory, visuospatial function, language, fatigue and mood. The Mann-Whitney U test was used to compare means between two groups. Binary logistic regression was also estimated. Lesion load in MRI was estimated using Statistical Parametric Mapping and the Lesion Segmentation Tool.
Results: Thirty-two patients were treated with fampridine. Twenty-four (75%) were considered time-walked responders according to the assessment of walking speed at 1 month, and 8 (25%) non-responders. There were no differences in demographic factors between both groups. The responder group obtained lower scores in backward visuospatial span, and in the Tower of London test (total correct and total movements scores). Regression analysis classified correctly the 80% of cases.
Conclusion: Higher-order executive function was associated to responsiveness to fampridine. This may suggest a possible role of conduction impairment in the pathogenesis of higher-order executive dysfunction in MS. Further studies are necessary to confirm this association.
Disclosure:
Matias-Guiu JA: nothing to disclose
Cortes-Martínez A: nothing to disclose
Villar-Quiles RN: nothing to disclose
Montero P: nothing to disclose
González-Suárez I: nothing to disclose
Oreja-Guevara C: nothing to disclose
Matis-Guiu J: nothing to disclose
Abstract: P576
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Neuropsychology
Background: Fampridine is an oral treatment that has been shown to promote the conduction in demyelinated axons in Multiple Sclerosis (MS). It acts blocking the potassium channels, improving the gait. Some central nervous system secondary effects may appear, but it does not seem to affect cognitive functions. Several factors (lesion mechanism, conduction impairment, etc.) have been associated to cognitive impairment in MS, although the pathogenesis of deficits in specific functions is under discussion. The aim of this study was to compare the cognitive performance between responders and non-responders to this treatment.
Methods: Retrospective study of a cohort of patients treated with fampridine. Walking speed was evaluated at baseline and 1 month after the onset of treatment. Exhaustive cognitive assessment was performed, using several tests of attention and executive function, processing speed, verbal and visual memory, visuospatial function, language, fatigue and mood. The Mann-Whitney U test was used to compare means between two groups. Binary logistic regression was also estimated. Lesion load in MRI was estimated using Statistical Parametric Mapping and the Lesion Segmentation Tool.
Results: Thirty-two patients were treated with fampridine. Twenty-four (75%) were considered time-walked responders according to the assessment of walking speed at 1 month, and 8 (25%) non-responders. There were no differences in demographic factors between both groups. The responder group obtained lower scores in backward visuospatial span, and in the Tower of London test (total correct and total movements scores). Regression analysis classified correctly the 80% of cases.
Conclusion: Higher-order executive function was associated to responsiveness to fampridine. This may suggest a possible role of conduction impairment in the pathogenesis of higher-order executive dysfunction in MS. Further studies are necessary to confirm this association.
Disclosure:
Matias-Guiu JA: nothing to disclose
Cortes-Martínez A: nothing to disclose
Villar-Quiles RN: nothing to disclose
Montero P: nothing to disclose
González-Suárez I: nothing to disclose
Oreja-Guevara C: nothing to disclose
Matis-Guiu J: nothing to disclose